QuidelOrtho (QDEL) COO awarded RSUs, stock options and net shares after tax withholding

Rhea-AI Filing Summary

QuidelOrtho Corp Chief Operations Officer Philip D. McLellan reported multiple equity compensation transactions. On January 30, 2026, he received 36,152 restricted stock units and 36,150 non-qualified stock options with a $27.17 exercise price, vesting in tranches from 2027 to 2029. On January 31, 2026, several blocks of restricted stock units converted into common stock, increasing his direct holdings, while the company withheld shares at $27.17 per share to cover tax obligations. After these transactions, he directly owned 19,174 shares of common stock, plus the newly granted RSUs and options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McLellan Philip D.

(Last) (First) (Middle)

9975 SUMMERS RIDGE ROAD

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operations Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A		1,127(1)	A	$0	17,311	D
Common Stock	01/31/2026		F		421(2)	D	$27.17	16,890	D
Common Stock	01/31/2026		A		847(1)	A	$0	17,737	D
Common Stock	01/31/2026		F		304(2)	D	$27.17	17,433	D
Common Stock	01/31/2026		A		2,009(1)	A	$0	19,442	D
Common Stock	01/31/2026		F		674(2)	D	$27.17	18,768	D
Common Stock	01/31/2026		A		634(1)	A	$0	19,402	D
Common Stock	01/31/2026		F		228(2)	D	$27.17	19,174	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	01/30/2026		A		36,152		(4)	(4)	Common Stock	36,152	$0	36,152	D
Non-Qualified Stock Options	$27.17	01/30/2026		A		36,150		(5)	01/30/2036	Common Stock	36,150	$0	36,150	D
Restricted Stock Units	(3)	01/31/2026		M			1,127	(6)	(6)	Common Stock	1,127	$0	0	D
Restricted Stock Units	(3)	01/31/2026		M			847	(7)	(7)	Common Stock	847	$0	0	D
Restricted Stock Units (Converted)	(3)	01/31/2026		M			2,009	(8)	(8)	Common Stock	2,009	$0	0	D
Restricted Stock Units (Premium )	(3)	01/31/2026		M			634	(8)	(8)	Common Stock	634	$0	0	D

Explanation of Responses:

1. Reflects release of restricted stock units that were previously reported on a Form 3 or Form 4.

2. Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.

3. Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.

4. 12,050 shares will vest on January 30, 2027; the remaining 24,102 shares will vest in equal installments on January 30, 2028 and January 30, 2029.

5. 36,150 shares will vest in equal installments on January 30, 2027, January 30, 2028 and January 30, 2029.

6. 2,254 shares vested in equal installments on January 31, 2025 and January 31, 2026.

7. 846 shares vested on January 31, 2025 and 847 shares vested on January 31, 2026.

8. Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule.

Remarks:

	/s/ Jennifer Ahn, attorney-in-fact for Philip D. McLellan	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did QuidelOrtho (QDEL) report for COO Philip McLellan?

QuidelOrtho reported equity compensation activity for COO Philip McLellan, including new restricted stock units, stock options, and the release of previously granted RSUs into common stock, along with share withholding to cover related tax obligations.

How many restricted stock units did the QuidelOrtho (QDEL) COO receive?

Philip McLellan received 36,152 restricted stock units. These units represent the right to receive one share of QuidelOrtho common stock each and vest over several years according to the schedule described in the filing footnotes.

What stock options were granted to the QuidelOrtho (QDEL) COO in this Form 4?

The filing shows a grant of 36,150 non-qualified stock options with a $27.17 exercise price. These options vest in equal installments on January 30, 2027, January 30, 2028, and January 30, 2029, subject to continued service conditions.

Why did QuidelOrtho (QDEL) withhold some of the COO’s shares in these transactions?

Shares were withheld to satisfy tax withholding obligations tied to the release of restricted stock units. Instead of paying cash for taxes, a portion of the newly issued common shares was surrendered back to the company at $27.17 per share.

How many QuidelOrtho (QDEL) common shares does the COO own after these transactions?

After the reported transactions, Philip McLellan directly owned 19,174 shares of QuidelOrtho common stock. This figure reflects the net result of RSU releases into stock and share withholding for taxes recorded in the Form 4.

How do the new QuidelOrtho (QDEL) RSUs for the COO vest over time?

Of the 36,152 new RSUs, 12,050 shares vest on January 30, 2027. The remaining 24,102 shares vest in equal installments on January 30, 2028 and January 30, 2029, according to the vesting schedule in the filing.